Loading...
XSHG
605507
, Last price  
Name

Guobang Pharma Ltd

Chart & performance

D1W1MN
XSHG:605507 chart
P/E
—
P/S
—
EPS
1.47
Vol. 1Y
—
Shs. 5Y
-0.15%
Rev. 5Y
7.32%
Div Yld LY
—
Div Yld TTM
—
Revenues
5.99b
+1.68%
2,905,475,1813,279,017,1823,802,036,2324,206,317,9524,505,350,5805,720,924,7215,349,447,8525,890,839,2055,989,647,725
Net income
821m
+5.02%
177,730,047210,872,486314,942,611810,000,082706,030,324920,904,234612,464,148781,595,429820,820,433
CFO
560m
-20.70%
148,033,000541,682,929440,863,592767,704,80301,017,033,878516,760,952706,410,855560,155,841
Dividend
May 29, 20260.6 /sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Guobang Pharma Ltd., a Chinese company, specializes in the research, development, manufacturing, and distribution of pharmaceutical products for both human and veterinary use within China. For human healthcare, their offerings encompass active pharmaceutical ingredients (APIs), intermediate compounds related to these APIs, and finished dosage forms. In the animal health sector, they provide veterinary APIs, various additives, and prepared formulations. The company was founded in 1996 and has its headquarters situated in Xinchang, China.
IPO date
Aug 02, 2021
Employees
Domiciled in
CN
Incorporated in
CN
Headquarters & legal address
浙江省新昌省级高新技术产业园区兴梅大道60号
绍兴市, ZJ 310000
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT